(August 21, 2020, Hong Kong) Kintor Pharmaceutical Limited (stock code: 9939, hereinafter referred to as “Kintor Pharmaceutical”) announced that Kintor Pharmaceutical and Gensun Biopharma Inc., (a holding subsidiary of Zelgen Biopharmaceuticals Co., Ltd. (stock code:688266.SH), hereinafter referred to as “Gensun”) signed an exclusive license agreement to promote the clinical development and commercialization of Gensun’s PD-L1/TGF-βdual-targeting antibody GS19 in Greater China (including the Chinese mainland, Hong Kong, Macau and Taiwan).

Dr. Youzhi TONG, Founder, Chairman and CEO of Kintor Pharmaceutical and Dr. Zelin SHENG, Founder, 
Chairman and CEO of Zelgen Biopharmaceuticals signed exclusive license agreement.

Under the agreement, Gensun will obtain up to US$23 million in total, including down payments and milestone payments based on registration and clinical development phases. In addition, Gensun will obtain a certain proportion of royalty payments based on the net sales of GS19 in Greater China.

According to Dr. Youzhi TONG, Founder, Chairman and CEO of Kintor Pharmaceutical, heis very pleased to reach this agreement with Gensun. The introduction of PD-L1/TGF-β dual-targeting antibody GS19 is a strategic step of Kintor Pharmaceutical during its layout in bio-pharmaceutical research and development, which only expands the company's product pipelines, but also brings more possibilities to explore cancer immunotherapies. Because GS19 is potentially the best-in-class oncotherapic drug, Kintor Pharmaceutical will accelerate its preclinical research and development for early IND registration application and clinical study. Meanwhile, the company will try to apply the combination of GS19 and potential first-in-class ALK-1 antibody in treating advanced liver cancer, and expect that GS19 could bring more and more effective solutions to tumor treatment.

According to Dr. Zelin SHENG, Founder, Chairman and CEO of Zelgen Biopharmaceuticals, he is very pleased to see the cooperation between Kintor Pharmaceutical and Gensun on GS19. Through the cooperation, Gensun's excellent dual-targeting research and development platform and product pipeline could be accepted and developed jointly by peers, and will ultimately provide patients with more effective, safe and affordable new drugs. He wished Kintor Pharmaceutical to develop GS19 successfully, so as to provide new momentum for its combined treatment and development of new strategies.

About GS19
GS19 is a PD-L1 and TGF-βR2 dual-targeting antibody, with a high activity in inhibiting both PD-L1 and TGF-βR2. Genetic engineering modification could reduce its degradation or fragmentation in CHO cell expression proteins, which makes it easier to be commercially produced and becomes a potential best-in-class drug. Gensun owns the global intellectual property right of GS19.

About Kintor Pharmaceutical Limited
Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialization of “best-in-class” and “first-in-class” innovative drugs, and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. The Company, after years of development, centered upon androgen receptor (AR) related diseases and researched and developed product portfolios in multiple channels covering cancers with a globally high incidence and illnesses yet to meet their clinical requirements, such as prostate cancer, breast cancer, liver cancer and hair loss. Kintor Pharmaceuticals has prospectively deployed a diversified product pipeline that includes small molecule innovative drugs, bio-innovative drugs and combination therapies, including 5 products that are undergoing clinically researched androgen receptor antagonists, ALK-1 monoclonal antibody, mTOR kinase inhibitors and Hedgehog inhibitors, as well as AR-Degrader, c-Myc inhibitors and IDO inhibitors that are undergoing preclinical research. Globally, the Company has more than 60 patents obtained or under review, many of which are listed as the “Major New Drugs Discovery” in National 12th and 13th Five-Year Plans. On 22 May 2020, the Company was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK. Visit http://www.kintor.com.cn for more information.

About Gensun Biopharma Inc.
Gensun Biopharma Inc., is a holding subsidiary of Zelgen Biopharmaceuticals Co., Ltd. (stock code: 688266.SH). Its main business is research and development of innovative antibody drugs, including research and development, licensing and marketing of biological drugs in the field of tumor immunity. Its new antibodies in pipeline include monoclonal antibodies, bispecific antibodies and trispecific antibodies. Gensun has established advanced antibody technology platforms and new antibody drug product lines. Currently, it has more than 10 preclinical projects in pipeline, focusing on research and development of tumor immunotherapy and tumor immune microenviroment-regulating antibody drugs. Welcome to the company’s website: www.gensunbiopharma.com

About Gensun Biopharma Inc.,
Founded in 2009, Gensun Biopharma Inc. is an innovation-driven chemical and biological new drug R&D and production enterprise dedicated to the treatment of tumors, hemorrhagic and blood diseases, hepatic and gall diseases, immune inflammatory diseases and some other diseases. It has successfully established two major platforms respectively for the R&D and industrialization of precision small-molecule drugs and complex recombinant protein drugs, set up three R&D centers, and developed a variety of product lines for small-molecule new drugs and recombinant protein new drugs; the 30 R&D projects it’s presently developing for 12 new drugs cover the treatment of several cancers, including liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharynx cancer and myeloproliferative disorders, as well as blood tumors, hemorrhagic disorders and hepatic and gall diseases. The new drugs presently under clinical trials include Donafenib tablets, Jaktinib tablets, Jaktinib ointments, Ocatinib capsules, recombinanthuman thrombin, recombinant human thyroid stimulating hormone for injection. It has applied for over 130 invention patents on a cumulative basis, more than 70 of which have been authorized in China, US and EU, etc. The company has successively undertaken five “major new drug creation” projects of the State, projects of fruit transfer in Jiangsu Province, projects under the National Technical Innovation Fund for Medium and Small-Size Enterprises, and dozens of scientific and technological projects at the provincial or municipal levels. Welcome to the company’s website: www.zelgen.com.